EyePoint, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was License And Collaboration Agreement at $16.7 million, 53% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
FY 2016
Jun 30, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3
|
31
|
43
|
46
|
41
|
37
|
34
|
20
|
3
|
8
|
2
|
| License And Collaboration Agreement |
1
-97.3%
share 35.8%
|
17
-56.5%
share 53.3%
|
38
+25.0%
share 89.0%
|
31
+8407.5%
share 66.9%
|
0
-52.1%
share 0.9%
|
1
-93.7%
share 2.0%
|
12
share 34.7%
|
—
|
—
|
—
|
—
|
| Royalty |
0
-96.7%
share 15.9%
|
13
+708.5%
share 41.6%
|
2
+63.1%
share 3.7%
|
1
-13.0%
share 2.1%
|
1
share 2.7%
|
—
|
2
share 4.8%
|
—
|
—
|
—
|
—
|
| DEXYCU Product |
—
|
—
|
—
|
—
|
12
-36.9%
share 28.0%
|
18
+164.0%
share 49.7%
|
7
share 20.2%
|
—
|
—
|
—
|
—
|
| Product |
1
-37.4%
share 48.4%
|
2
-49.6%
share 5.1%
|
3
-77.8%
share 7.3%
|
14
-64.3%
share 30.9%
|
40
+13.0%
share 96.4%
|
35
share 95.6%
|
—
|
—
|
—
|
—
|
—
|
| Collaborative Research And Development |
—
|
—
|
—
|
—
|
—
|
0
-76.5%
share 0.2%
|
0
share 0.7%
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- EYPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1314102
- Former names
- EyePoint Pharmaceuticals, Inc. (until Dec 8, 2025); pSivida Corp. (until Mar 30, 2018); pSivida LTD (until Jun 18, 2008)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Source: SEC EDGAR filings. This is company-reported data, not investment advice.